PsiloThera, Inc.
Psychedelic Healthcare Innovation
Henderson, NV
Biotechnology
Psilothera is a pioneering mental health care company dedicated to creative, modern solutions to treat global healthcare concerns, including depression, anxiety, PTSD, eating disorders, addictions, Alzheimer’s, dementia, and more. We plan to deploy quantum technology to shorten the drug development time, which will give us an advantage over our competitors. With a focus on healing, hope, and compassion, we aim to change the paradigm of mental healthcare with their Psilocybin-based therapies.
$135,846
raised
127
Investors
$50M
Valuation
$5.00
Price per Share
$500.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$5M
Offering Max
Reg CF
Offering
Rewards
Get rewarded for investing more into PsiloThera, Inc.:
$500+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$50,000+
Investment
Tier 1: $50,000+
Invest $50,000 or more and receive 5% bonus shares
$75,000+
Investment
Tier 2: $75,000+
Invest $75,000 or more and receive 7% bonus shares
$100,000+
Investment
Tier 3: $100,000+
Invest $100,000 or more and receive 10% bonus shares
Reasons to Invest
Psilothera is stepping into the scene of major healthcare crisis by focusing on medical research breakthroughs and groundbreaking legalizations
The company is actively targeting a $100 billion market opportunity in Psilocybin healthcare
Psilothera is led by a battle tested management team with business model, strategy and plan driven by research and development
The Problem
The world is in the throes of a mental health crisis
Recent estimates from the World Health Organization show that roughly 322 Million People suffer from Major Depression Disorder. In the US alone, 16 million people suffer from this debilitating disease. What’s worse is that up to a third of the people suffering from clinical depression are “treatment resistant,” meaning traditional antidepressants don’t treat them. This resistance is one of the reasons why 17.6 veterans commit suicide a day in the United States. With the current state of the mental healthcare industry, they have no other options for medication.
A recent Gallup poll shows that the pharmaceutical industry is the least trusted industry in America. Toxic industry norms, widespread corruption, as well as harsh side effects of mental health medicine have created a need for a viable alternative among patients and consumers. (Source)
THE SOLUTION
Psilocybin-based therapy is revolutionizing the world of mental healthcare
Psilothera commits to providing new remedies for mental wellness by creating compounds for Psilocybin-based treatments. Psilocybin assisted therapy gives the patient the opportunity to fully engage in self-reflection and personal expression, ultimately shift emotional and behavior patterns.
The technique used in Psilocybin assisted therapy is microdosing. Microdosing is the regular intake of very small quantities of psychedelic substances. Microdosing is beneficial because while there are minimal acute effects reported, these substances claim a range of long-term health and well-being benefits. We believe the fear of having a “bad trip” on Psilocybin makes microdosing a more approachable option for the millions of people suffering.
THE MARKET
Vertical integration powered by quantum technology
Psilothera’s battle tested leadership team is made up of entrepreneurs, mental health professionals, and mushroom farmers. This team agrees on the same mission: be one of the first companies focused on developing Psilocybin-based therapeutics while deploying quantum technology. We are currently in the final stages of procuring a technology licensing agreement with a well-known quantum technology company, which will drastically reduce the development time as well as the cost of therapeutics.
OUR TRACTION
Gaining momentum by the day
Breakthrough studies by reputable programs such as Journal of JAMA Psychiatry, Johns Hopkins Center for Psychedelic & Consciousness Research, Imperial College, and US National Library of Medicine National Institute of Health have all shown promising results on psychedelics’ ability to treat long-lasting depressive, PTSD, and anxiety symptoms with minimal side effects.
Psilothera’s partnership with the Zoom Healthcare ISV Program to develop its tele-health mental health care video platform is paving the way for groundbreaking development in online Psilocybin-based treatment.
Psilothera is pre-revenue and our Fungi Grow & Lab is in its pre-launch stage. Once launched, the lab will begin researching, growing, and developing 20 different types of Psilocybe Cubensis, providing us with a robust portfolio of therapeutic fungi.
The varieties of mushrooms to be used in our formulations include Reishi, Lion’s Mane, Turkey Tail, Shiitake, Maitake, and Oyster. Reishi, for example, is being studied and used for its anticancer potential at the Memorial Sloan Kettering Cancer Center. Our Mushroom Nutraceutical product line for cancer patients is designed to support their current treatments program.
On a global scale, in November 2020, Oregon became the first state in the United States to legalize Psilocybin, allowing supervised use of psilocybin in a therapeutic setting.
Furthermore, voters around the country have decriminalized in Washington DC, Denver, Oakland, Ann Arbor, Houston, Somerset and Cambridge, MA so far. Psilothera projects widespread movement towards Legalization and Decriminalization by 2023.
WHY INVEST
The time to invest is now
A major paradigm shift is occurring in the healthcare sector. Breakthrough medical studies, a string of groundbreaking legalizations, and an unprecedented public openness to psychedelics has paved the road for Psilocybin-based therapy to be a legitimate alternative to pharmaceutical products. Psilothera aims to deploy this cutting edge medicine to establish itself as a beacon of hope, wellness, and compassion in the mental health market.
gif
Annual sales for antidepressants, ADHD, anxiety, and anti-addiction medications well exceed $30 billion, and an increasing number of studies are showing a potential for Psilocybin and other psychedelic-based therapies to be as or even more effective than their pharmaceutical counterparts, meaning potential billions in revenue.
Our mushrooms aren't magic. They're therapeutic, backed by science. We believe they're the future of mental health treatment.
Offering Summary
Company | : | PsiloThera, Inc. |
Corporate Address | : | 17 Cerchio Basso, Henderson, NV 89011 |
Offering Minimum | : | $10,000.00 |
Offering Maximum | : | $5,000,000.00 |
Minimum Investment Amount(per investor) | : | $500.00 |
Terms
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 2,000 |
Maximum Number of Shares Offered | : | 1,000,000 |
Price per Share | : | $5.00 |
Pre-Money Valuation | : | $50,000,000.00 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below. Note these perks do stack with the other offering perks. You will only receive the highest level bonus share perk you are eligible for.
Company Perks*
Time-Based Perks
Friends & Family Bonus
Invest in the first 72 hours and receive 10% bonus shares.
Amount-Based Perks
Tier 1: $50,000+
Invest $50,000 or more and receive 5% bonus shares
Tier 2: $75,000+
Invest $75,000 or more and receive 7% bonus shares
Tier 3: $100,000+
Invest $100,000 or more and receive 10% bonus shares
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Psilothera will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $5.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $500. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Irregular Use of Proceeds
The Company will not incur any irregular use of proceeds.
Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$0.00
USD
$0.00
USD
Cash And Cash Equivalents
$0.00
USD
$0.00
USD
Accounts Receivable
$0.00
USD
$0.00
USD
Short Term Debt
$0.00
USD
$0.00
USD
Long Term Debt
$0.00
USD
$0.00
USD
Revenues And Sales
$0.00
USD
$0.00
USD
Costs Of Goods Sold
$0.00
USD
$0.00
USD
Taxes Paid
$0.00
USD
$0.00
USD
Net Income
$0.00
USD
$0.00
USD
Risks
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Updates
Psilothera CEO John Atanasio to Speak at The Cannabis Investment Summit.- Feb 2nd
2 days agoHi Psilothera Investors
Psilothera CEO John Atanasio to Speak at The Cannabis Investment Summit.- Feb 2nd. Happy to be invited and this gives Psilothera another platform to share our story.
John Atanasio, CEO
Notice of Funds Disbursement
3 days ago[The following is an automated notice from the StartEngine team].
Hello!
As you might know, PsiloThera, Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PsiloThera, Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
Psilothera to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference - December 6, 2021.
3 days agoHi Startengine Investors,
Psilothera to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference - December 6, 2021.
This is a great platform to share our story.
We have over 400 investors watching on the Startengine.
We have outstanding momentum and please invest now.
John Atanasio, CEO
Psilothera's CEO John Atanasio on Stage at Wonderland Miami 2021-Video
10 days agoHi StartEngine Investors
Psilothera's CEO John Atanasio on Stage at Wonderland Miami 2021 Video
Notice of Funds Disbursement
18 days ago[The following is an automated notice from the StartEngine team].
Hello!
As you might know, PsiloThera, Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PsiloThera, Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
Psilothera video CEO Presents at PsyCap Psychedelic Investor Conference
24 days agoHi Startengine Investors,
I was recently a presenter at the PsyCap an Online Psychedelic Investor Conference that took place.Last week and below is some video.
PSILOTHERA- Quantum Technology Comments and Article
25 days agoHi Startengine Investors
A few of you asked about Quantum Technology. Below is a link to a article that also discusses Drug Discovery. We believe that being an early leader using Quantum Technology and AI in our labs is critical.
I believe Quantum Technology may be game changing next level technology and worth pursuing.
John Atanasio, CEO
Seattle Votes to Decriminalize Psilocybin
29 days agoHi Startengine Investors,
Seattle Votes to Decriminalize Psilocybin.
This is huge as the City Council has indicated that are following the lead of Oregon.
Psilothera shall apply for Licensing on Oregon and other markets as they become available. Oregon shall commence its licensing application process in January 2023.
Psilothera to Sponsor Wonderland- Miami
about 1 month agoPsilothera is proud to announce that we will be a major sponsor of Wonderland- Miami, the 1st and largest major Psychedelic Conference of its kind. The Genie is out of the bottle ... the World will know about Psilothera.
Psilothera- Psychedelic Capital Conference Presentation & Free Ticket
about 1 month agoIf you missed the Psychedelic Capital event you can still view the entire event online.
Just go to link and type JOHNA or Psilothera for free ticket
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}